Mesenchymal Stem Cell Tendon Regeneration Kit
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for soft skeletal tissue injuries, such as tendon and ligament injuries in competitive animals, are ineffective in regenerating tissue and often lead to re-injury and poor functional outcomes, with methods like beta-aminoproprionitrile fumarate showing adverse effects and limited success in clinical trials.
Innovation Solution
A method involving the isolation, characterization, and expansion of autologous mesenchymal stem cells (MSCs) for re-implantation into damaged tendons, using enriched compositions of MSCs or tenocytes derived therefrom, to promote regeneration of tendon tissue.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If bone marrow is injected directly into damaged tendon, then mesenchymal stem cells are delivered to the injury site, but large volumes of injection cause disruption of remaining intact tendon tissue and include deleterious components such as bone spicules and fat cells
Solution Approach 1:
The patent extracts only the beneficial mesenchymal stem cells from bone marrow by culturing and isolating them in vitro, separating them from harmful components like bone spicules and fat cells. This allows delivery of concentrated MSCs without the deleterious elements present in raw bone marrow aspirates.
Solution Approach 2:
The patent uses an in vitro culture system as an intermediary between the bone marrow source and the tendon injury site. This intermediate step allows for cell expansion, purification, and quality control, transforming raw bone marrow into a refined cell product that can be delivered in smaller, safer volumes.
2Quantity of substance
If large volumes of bone marrow are injected into the tendon, then more mesenchymal stem cells are delivered, but considerable disruption of the remaining intact tendon tissue occurs
Solution Approach 1:
The patent performs preliminary expansion of mesenchymal stem cells in vitro before injection, allowing a small initial sample to be cultured into a large number of cells. This preliminary action enables delivery of high cell doses without requiring large injection volumes that would disrupt tendon tissue.
Solution Approach 2:
The patent changes the concentration parameter of mesenchymal stem cells by expanding them in culture, transforming a dilute mixture in raw bone marrow into a concentrated cell product. This parameter change allows delivery of sufficient cells in small volumes that do not disrupt tendon integrity.
3Ease of manufacture
If current treatment regimes are used for tendon injuries, then treatment can be administered, but only marginal effects on outcome are achieved and re-injury incidence remains high
Solution Approach 1:
The patent uses autologous mesenchymal stem cells harvested from the patient's own bone marrow, allowing the patient's own cells to perform the repair function. This self-service approach eliminates immune rejection issues and provides personalized regenerative therapy that addresses the root cause of poor outcomes with conventional treatments.
Solution Approach 2:
The patent changes the biological quality of the treatment by introducing living mesenchymal stem cells that can differentiate into tenocytes and regenerate tendon matrix, rather than using passive treatments. This parameter change from chemical/physical therapy to cellular therapy fundamentally improves reliability of functional outcomes.
4Stability of the object's composition
If lysyl oxidase inhibitor beta-aminoproprionitrile fumarate is used, then collagen cross-linking is controlled allowing exercise regime to improve scar tissue functionality, but the treatment does not regenerate tendon tissue and may have adverse effects
Solution Approach 1:
The patent converts the limitation of scar tissue formation into a benefit by using mesenchymal stem cells that can differentiate into tenocytes and produce new tendon matrix rather than scar tissue. This transforms the harmful outcome of conventional healing into a beneficial regenerative process.
Solution Approach 2:
The patent changes the regenerative capacity parameter by introducing mesenchymal stem cells that possess the ability to differentiate into tendon-specific cells, fundamentally altering the healing process from scar formation to true tissue regeneration with restored functionality.
Data Source
AI summary
A method of treating a natural soft skeletal tissue injury in a patient the method comprising administering to the patient a composition of mesenchymal stem cells in liquid suspension enriched compared to the natural source of said cells, or tenocytes derived therefrom. The method is particularly suited to the regeneration of tendons in competitive mammals, such as the superficial digital flexor tendon of the horse.